Yuan‐Hung Wang

SGLT2 Inhibitors for Steatosis and Noninvasive Liver Markers in MASLD: A Meta-analysis of Randomized Trials

Abstract Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to cardiometabolic dysfunction, yet liver-specific pharmacological options remain limited. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been proposed as potential the...